Terms: = Bone cancer AND MYD88, Q99836, MYD88D, 4615 AND Prognosis
12 results:
1. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
2. Multiple Genomic Alterations, Including a Novel
Sahin Y; Wang YL; Pei J; Mansoor N; Styler M; Testa JR; Nejati R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203475
[TBL] [Abstract] [Full Text] [Related]
3. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
Jakubikova J; Cholujova D; Beke G; Hideshima T; Klucar L; Leiba M; Jamroziak K; Richardson PG; Kastritis E; Dorfman DM; Anderson KC
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752202
[TBL] [Abstract] [Full Text] [Related]
4. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F; Dogan A; Cook JR
Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
[TBL] [Abstract] [Full Text] [Related]
5. [Waldenström disease: News and perspectives in 2022].
Bouclet F; Krzisch D; Leblond V; Tomowiak C; Laribi K; Ysebaert L; Tournilhac O; Dartigeas C; Leprêtre S; Jondreville L;
Bull Cancer; 2023 Jan; 110(1):88-100. PubMed ID: 36229266
[TBL] [Abstract] [Full Text] [Related]
6. Human myd88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
[TBL] [Abstract] [Full Text] [Related]
7. T-Cell Deletion of myd88 Connects IL17 and IκBζ to RAS Oncogenesis.
Cataisson C; Salcedo R; Michalowski AM; Klosterman M; Naik S; Li L; Pan MJ; Sweet A; Chen JQ; Kostecka LG; Karwan M; Smith L; Dai RM; Stewart CA; Lyakh L; Hsieh WT; Khan A; Yang H; Lee M; Trinchieri G; Yuspa SH
Mol Cancer Res; 2019 Aug; 17(8):1759-1773. PubMed ID: 31164412
[TBL] [Abstract] [Full Text] [Related]
8. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract] [Full Text] [Related]
9. Waldenström macroglobulinemia treatment algorithm 2018.
Gertz MA
Blood Cancer J; 2018 May; 8(4):40. PubMed ID: 29712895
[TBL] [Abstract] [Full Text] [Related]
10. Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity.
Bonilla-Valentín FJ; Cerra J; Cáceres-Perkins W; Alsina M
Cancer Control; 2018; 25(1):1073274817744448. PubMed ID: 29318955
[TBL] [Abstract] [Full Text] [Related]
11. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract] [Full Text] [Related]
12. Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Castillo JJ; Ghobrial IM; Treon SP
Cancer Treat Res; 2015; 165():177-95. PubMed ID: 25655610
[TBL] [Abstract] [Full Text] [Related]
